• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

New possible Cushings treatments work at root cause

November 12, 2015
David S. Bruyette, DVM, DACVIM

Prominent endocrinologist says veterinarians may soon be able to do more than treat clinical signs.

Dr. Dave BruyetteEvery year an estimated 90,000 to 100,000 new cases of Cushing's disease are diagnosed in geriatric dogs, making it the most common endocrine disease in older canine patients. Many of these cases are treated with drugs such as mitotane or trilostane, which reduce cortisol and help with clinical signs, but neither works at the level of the pituitary.

David S. Bruyette, DVM, DACVIM, medical director VCA West Los Angeles Animal Hospital, says dopaminergic drugs may provide another treatment option that does just that. “Historically we've used medications that attack the adrenal; we don't address the primary problem, which is the pituitary tumor,” Bruyette told dvm360 recently.

Up to 40 percent of these tumors overexpress the D2 dopamine receptor in dogs, he says, and drugs that bind with high affinity to the dopaminergtic receptor actually shrink the tumors. They also decrease adrenocorticotropic hormone (ACTH) production, which then lowers cortisol-so these drugs treat clinical signs of Cushing's as well.

“There is a drug commercially available called cabergoline that was used in a large number of dogs in a study out of Argentina, and the drugs seem quite effective in normalizing clinical signs as well as shrinking the tumors-at least in dogs with relatively small tumors,” Bruyette says.

Advertisement

Further studies have examined the receptor abnormalities expressed by the pituitary tumors that cause Cushing's, he continues. Researchers are actively looking at epithelial growth factor receptor (EGFR) antagonists as well as somatostatin receptor antagonists.

Bruyette says use of a human drug called pasireotide, an SST2 receptor antagonist, looks promising for treatment of dogs as well. “A recent study in dogs with fairly small tumors showed that not only did they get reductions in ACTH and reductions in urine cortisol-creatinine ratios but also modest shrinkage in some of these tumors,” he says.

Larger studies will examine whether use of drugs such as pasireotide are effective for treating dogs with larger tumors without radiation and surgery.

“Hopefully, some of these newer treatments that have recently come available for humans will become available for use in the dog,” Bruyette says.

Related Content:

MedicalEndocrinology
Tips and tricks for diagnosing canine osteoarthritis early
Tips and tricks for diagnosing canine osteoarthritis early
Performing surgery on dogs with GDV
Performing surgery on dogs with GDV
Not-so-ordinary ER cases you should know
Not-so-ordinary ER cases you should know

Advertisement

Latest News

Updated EquiTrace app integrates wth HISA Portal

San Francisco SPCA bestows $100k grant from San Francisco Foundation

Merck Animal Hospital renews scholarship with The Foundation for the Horse

3 Must-reads from Fetch Charlotte 2023

View More Latest News
Advertisement